A&D HOLON Holdings Company, Limited
7745・Prime Market・Precision Instruments
Business
A&D Holon Holdings Co., Ltd. develops three business segments—Semiconductor-related Business (photomask dimension measurement equipment, converters, etc.), Measurement & Weighing Equipment Business (material testing machines, electronic balances, foreign object inspection equipment, etc.), and Medical & Health Equipment Business (blood pressure monitors, biological information monitors, etc.)—centered on its 'measurement' technology rooted in A/D・D/A Converters technology. Through 20 consolidated subsidiaries in Japan and overseas, the company has built a global manufacturing and sales structure spanning Japan, Americas, Europe, and Asia & Oceania. Its major customers range widely across semiconductor manufacturers, manufacturing companies, medical institutions, and general consumers, with consolidated net sales reaching ¥69,326 million in FY2026 (ending March 2026).
Business Model
The company develops high-precision measurement equipment through in-house R&D (R&D expenses of ¥5,695 million, with 397 R&D staff, approximately 16.0% of total employees), and manufactures it at domestic and overseas production sites. Products are sold across multiple regions and industries through a global network of sales and service subsidiaries. The Semiconductor-related Business is a highly profitable segment with an operating margin of 32.6%, while the Measurement & Weighing Equipment and Medical & Health Equipment businesses form a stable earnings base, with the diversified structure of these three businesses supporting overall earnings stability.
Company Strengths
The Semiconductor-related Business achieved an outstanding operating margin of 32.6% in FY2026 (ending March 2026) (net sales of ¥11,114 million, operating profit of ¥3,628 million). Horon Corporation developed the next-generation CD-SEM "HSS-1000" for EUV masks, achieving world-class measurement precision that supports the 1.6nm node and beyond. A&D Company, Ltd. provides core electron gun units, among other irreplaceable technological assets held by the group.
The Semiconductor, Measurement & Weighing Equipment, and Medical & Health Equipment segments diversify revenue across Japan, Americas, Europe, and Asia & Oceania. In FY2026 (ending March 2026), while the Semiconductor-related Business entered an adjustment phase, the Measurement & Weighing Equipment Business (net sales of ¥31,545 million, operating profit up 25.2% year on year) and Medical & Health Equipment Business (net sales of ¥26,667 million, up 10.5% year on year) complemented this, resulting in increased consolidated net sales and operating profit.
R&D expenses in FY2026 (ending March 2026) remained at a high level of ¥5,695 million (approximately 8.2% of net sales). The company employs 397 R&D staff (approximately 16.0% of all employees), continuously launching new products across the semiconductor, measurement, and medical fields. During the period, the company developed and launched multiple new products, including a next-generation CD-SEM, a semi-micro balance, and a hoseless blood pressure monitor, with continuous renewal of the product lineup serving as a source of competitiveness.
ENVALITH's Perspective
Performance Trend
Net sales for FY2026 (ending March 2026) came to ¥69,326 million (up 3.3% year on year), and operating profit reached ¥9,209 million (up 4.5% year on year), marking the fifth consecutive year of higher revenue and operating profit and setting a new record high for operating profit. On the other hand, profit attributable to owners of parent declined to ¥5,923 million (down 8.4% year on year). The main cause was the recording of ¥795 million in special losses, comprising a provision for losses related to the Measurement Act of ¥552 million and a loss of ¥243 million from embezzlement at a Korean subsidiary. By segment, the Semiconductor-related Business entered an adjustment phase, with revenue down 9.6% and profit down 12.0% year on year, while the Measurement & Weighing Equipment Business (operating profit up 25.2% year on year) and the Medical & Health Equipment Business (revenue up 10.5% year on year) provided support. For FY2027 (ending March 2027), the company forecasts a significant decline in operating profit to ¥7,000 million (down 24.0% year on year), and has also announced that it will revise its medium-term management plan. External factors such as US tariff policy, geopolitical risk, and foreign exchange fluctuations (the earnings forecast assumes an exchange rate of ¥150 to the US dollar) are expected to continue affecting performance.
Growth Strategy
Under a revised medium-term management plan, the company aims to strengthen profitability across its three business segments and achieve sustainable enhancement of corporate value.
With an eye on the medium- to long-term trend of expanding demand, the company is strengthening its global sales and service framework while expanding its product lineup through new product development. In FY2026 (ending March 2026), it carried out large-scale capital investment, with an increase in tangible and intangible fixed assets of ¥2,302 million, establishing the foundation for enhanced supply capacity and next-generation equipment development.
While capturing solid demand in Japan and Asia & Oceania, the company secured stable earnings in the Americas—affected by restraint in EV-related investment—by deepening its existing business there. In response to more sophisticated measurement needs driven by tightening environmental regulations and progress in automation, the company is expanding target industries and application fields. In FY2026 (ending March 2026), operating profit rose significantly to ¥3,387 million (up 25.2% year on year).
Amid progress in medical DX, the company is capturing expanding demand in the Americas and Europe while pursuing cost reduction and price optimization in response to rising costs from US tariff policy and overseas inflation. It aims for stable and sustainable business growth through expanded sales of high-value-added products and a focus on growth areas. In FY2026 (ending March 2026), sales in Europe increased 20.2% year on year, reflecting the effects of changes in distribution channels and foreign exchange.
In light of recent global economic trends and changes in the business environment, the company announced a revision of its medium-term management plan, which began in FY2026 (ending March 2026) as its first year. While maintaining the basic theme and direction of its growth strategy, the company intends to further strengthen the profitability of each business to ensure a recovery in performance from next fiscal year onward and a return to a medium- to long-term growth trajectory. New numerical targets have not yet been disclosed.
Last updated: July 19, 2026